Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BMS-986504 plus nab-paclitaxel/gemcitabine versus placebo plus nab-paclitaxel/gemcitabine in untreated metastatic MTAP-deleted pancreatic ductal adenocarcinoma
NL-OMON59646Phase 3Not yet recruiting
- Sponsor
- Bristol Myers Squibb
- Start
- May 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in pancreatic adenocarcinoma (PDAC) comparing BMS-986504 + nab-paclitaxel + gemcitabine with Placebo + nab-paclitaxel + gemcitabine (2 arms). Primary endpoints: Time to disease worsening on scans and Overall survival. Planned start May 2026; status: not yet recruiting.
02
Drugs
MRTX1719
03
Conditions
pancreatic adenocarcinoma (PDAC)
Beyond the preview
Go deeper on NL-OMON59646.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON59646.